Insider Selling: USANA Health Sciences (NYSE:USNA) Insider Sells $97,288.90 in Stock

USANA Health Sciences, Inc. (NYSE:USNAGet Free Report) insider Brent Neidig sold 5,002 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

USANA Health Sciences Trading Up 0.6%

Shares of USNA stock opened at $19.00 on Friday. The company has a market cap of $350.74 million, a P/E ratio of 40.43, a PEG ratio of 0.74 and a beta of 0.76. The firm has a fifty day moving average price of $18.77 and a 200 day moving average price of $19.41. USANA Health Sciences, Inc. has a 12 month low of $16.60 and a 12 month high of $38.32.

USANA Health Sciences (NYSE:USNAGet Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.17. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.The business had revenue of $250.22 million for the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. On average, equities analysts forecast that USANA Health Sciences, Inc. will post 2.12 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. State of Alaska Department of Revenue increased its holdings in USANA Health Sciences by 8.5% in the 4th quarter. State of Alaska Department of Revenue now owns 6,666 shares of the company’s stock valued at $130,000 after buying an additional 525 shares during the period. Russell Investments Group Ltd. boosted its position in shares of USANA Health Sciences by 4.6% during the 4th quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock valued at $244,000 after acquiring an additional 542 shares in the last quarter. Quantbot Technologies LP boosted its position in shares of USANA Health Sciences by 19.5% during the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after acquiring an additional 646 shares in the last quarter. Intech Investment Management LLC increased its stake in USANA Health Sciences by 13.5% in the third quarter. Intech Investment Management LLC now owns 7,722 shares of the company’s stock valued at $213,000 after acquiring an additional 918 shares during the period. Finally, National Bank of Canada FI raised its position in USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after purchasing an additional 1,201 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on USNA shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a report on Friday, March 27th. Wall Street Zen upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Zacks Research cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, USANA Health Sciences currently has an average rating of “Reduce”.

Check Out Our Latest Stock Analysis on USANA Health Sciences

About USANA Health Sciences

(Get Free Report)

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

Featured Articles

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.